Managing bipolar I disorder (BD-I) is a long-term commitment, and factors such as symptoms and side effects influence ...

In its new update, Moderna said that it had held a meeting with the FDA's Center for Biologics Evaluation and Research (CBER) ...

For the last three years, Bayer has been implementing a new strategy for its oncology development, a strategy that led to multiple approvals, as well as a number of promising new programmes added to ...

The FDA has started a priority review of iberdomide as an add-on to Johnson & Johnson and Genmab's anti-CD38 antibody Darzalex (daratumumab) and dexamethasone, a standard regimen for relapsed or ...

The analysis by property advisory firm Knight Frank found a 22% increase in the number of life science companies domiciled in the UK between 2019 and the end of 2025, to a total of 15,436.

Novartis is on course to expand the label for its recently approved oral BTK inhibitor Rhapsido, after chalking up a win in chronic skin disorder chronic inducible urticaria (CINDU).

As we traverse 2026, here are the five forces reshaping pharma commercialisation. Most pharma AI projects stall during data engineering, not model development. Commercial, R&D, manufacturing, and ...

January was a relatively quiet month for Board news, but there were some notable moves here and there. Read on for the full report.

An enzyme replacement therapy developed by Immedica, the first drug for the inherited metabolic disorder arginase-1 (ARG1) deficiency that can alter the course of the disease, has been cleared for NHS ...

Following his return from San Francisco and the JP Morgan Healthcare conference last month, editor-in-chief Jonah Comstock ...

Leadership is entering a new era, shaped by the rise of agentic AI systems capable of taking initiative, making decisions, ...

The approval of Exdensur (depemokimab) for severe asthma and chronic rhinosinusitis with nasal polyps by the European ...